| Name | Title | Contact Details |
|---|
At Elite Body Sculpture our biggest focus is making sure that every client that walks out the door is not just satisfied, but elated with their new, trimmer, sexier body. How do we do that? Mainly, we focus on liposuction and ONLY liposuction. At ...
The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.
Waters Edge Dermatology treats pediatric, adult and senior skincare patients in warmly welcoming, well-appointed offices across South & Central Florida; providing medical, surgical & cosmetic dermatology services, and state-of-the-art skin cancer dete...
Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.